Incidence of renal toxicity in HIV-infected, antiretroviral-naïve patients starting tenofovir/emtricitabine associated with efavirenz, atazanavir/ritonavir, or lopinavir/ritonavir

References

• Izzedine H, Harris M, Perazella MA. The nephrotoxic effects of HAART. Nat Rev Nephrol 2009;5:563–73.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Novoa S, Labarga P, Soriano V, Egan D, Albalate M, Morello J, . Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis 2009;48:E108–16.
   Web of Science ®Google Scholar
• Fux CA, Simcock M, Wolbers M, Bucher HC, Hirschel B, Opravil M, . Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study. Antivir Ther 2007;12:1165–73.
   PubMed Web of Science ®Google Scholar
• Izzedine H, Hulot JS, Vittecoq D, Gallant JE, Staszewski S, Launay-Vacher V, . Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naïve HIV-1-infected patients. Data from a double-blind randomized active- controlled multicenter study. Nephrol Dial Transplant 2005; 20:743–6.
   PubMed Web of Science ®Google Scholar
• Madeddu G, Bonfanti P, De Socio G, Carradori S, Grosso C, Marconi P, . Tenofovir renal safety in HIV-infected patients: results from the SCOLTA project. Biomed Pharmacother 2008;62:6–11.
   PubMed Web of Science ®Google Scholar
• Roling J, Schmid H, Fischereder M, Draenert R, Goebel FD. HIV-associated renal diseases and highly active antiretroviral therapy-induced nephropathy. Clin Infect Dis 2006;42:1488–95.
   PubMed Web of Science ®Google Scholar
• Izzedine H, Valantin MA, Daudon M, Mohand HA, Caby F, Katlama C. Efavirenz urolithiasis. AIDS 2007;21: 1992.
   PubMed Web of Science ®Google Scholar
• Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, . Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006;145:247–54.
   PubMed Web of Science ®Google Scholar
• Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, . National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003;139:137–47.
   PubMed Web of Science ®Google Scholar
• Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute renal failure—definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004;8: R204–12.
   PubMed Web of Science ®Google Scholar
• Calza L, Trapani F, Tedeschi S, Piergentili P, Manfredi R, Colangeli V, . Tenofovir-induced renal toxicity in 324 HIV-infected, antiretroviral-naïve patients. Scand J Infect Dis 2011;43:656–60.
   PubMed Web of Science ®Google Scholar
• Fernandez-Fernandez B, Montoya-Ferrer A, Sanz AB, Sanchez-Nino MD, Izquierdo MC, Poveda J, . Tenofovir nephrotoxicity: 2011 update. AIDS Res Treat 2011;2011: 354908.
   PubMedGoogle Scholar
• Hall AM, Hendry BM, Nitsch D, Connolly JO. Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. Am J Kidney Dis 2011;57:773–80.
   PubMed Web of Science ®Google Scholar
• Kohler JJ, Hosseini SH. Subcellular renal proximal tubular mitochondrial toxicity with tenofovir treatment. Methods Mol Biol 2011;755:267–77.
   PubMedGoogle Scholar
• Gayet-Ageron A, Ananworanich J, Jupimai T, Chetchotisakd P, Prasithsirikul W, Ubolyam S, . No change in calculated creatinine clearance after tenofovir initiation among Thai patients. J Antimicrob Chemother 2007;59:1034–7.
   PubMedGoogle Scholar
• Herlitz LC, Mohan S, Stokes MB, Radhakrishnan J, D’Agati VD, Markowitz GS. Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities. Kidney Int 2010;78:1171–7.
   PubMed Web of Science ®Google Scholar
• Smith KY, Patel P, Fine D, Bellos N, Sloan L, Lackey P, . Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS 2009;23: 1547–56.
   PubMed Web of Science ®Google Scholar
• Viganò A, Bedogni G, Manfredini V, Giacomet V, Cerini C, di Nello F, . Long-term renal safety of tenofovir disoproxil fumarate in vertically HIV-infected children, adolescents, and young adults: a 60-month follow-up study. Clin Drug Investig 2011;31:407–15.
   PubMed Web of Science ®Google Scholar
• Hall AM, Edwards SG, Lapsley M, Connolly JO, Chetty K, O’Farrell S, . Subclinical tubular injury in HIV-infected individuals on antiretroviral therapy: a cross-sectional analysis. Am J Kidney Dis 2009;54:1034–42.
   PubMed Web of Science ®Google Scholar
• Horberg M, Tang B, Towner W, Silverberg M, Bersoff-Matcha S, Hurley L, . Impact of tenofovir on renal function in HIV-infected, antiretroviral-naïve patients. J Acquir Immune Defic Syndr 2010;53:62–9.
   PubMed Web of Science ®Google Scholar
• Déti EK, Thiébaut R, Bonnet F, Lawson-Ayayi S, Dupon M, Neau D, . Prevalence and factors associated with renal impairment in HIV-infected patients, ANRS C03 Aquitaine Cohort, France. HIV Med 2010;11:308–17.
   PubMed Web of Science ®Google Scholar
• Mocroft A, Kirk O, Reiss P, De Wit S, Sedlacek D, Beniowski M, . Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS 2010;24:1667–78.
   PubMed Web of Science ®Google Scholar
• Tordato F, Cozzi Lepri A, Cicconi P, De Luca A, Antinori A, Colangeli V, . Evaluation of glomerular filtration rate in HIV-1-infected patients before and after combined antiretroviral therapy exposure. HIV Med 2011;12:4–13.
   PubMed Web of Science ®Google Scholar
• Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis 2010;51:496–505.
   PubMed Web of Science ®Google Scholar
• Scherzer R, Estrella M, Li Y, Deeks SG, Grunfeld C, Shlipak MG. Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS 2012;26:867–75.
   PubMed Web of Science ®Google Scholar
• O’Donnell EP, Scarsi KK, Darin KM, Gerzenshtein L, Postelnick MJ, Palella FJ Jr.Low incidence of renal impairment observed in tenofovir-treated patients. J Antimicrob Chemother 2011;66:1120–6.
   PubMed Web of Science ®Google Scholar
• Vrouenraets SM, Wit FW, Fernandez-Garcia E, Moyle GJ, Jackson AG, Allavena C, . Randomized comparison of metabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients. HIV Med 2011;12:620–31.
   PubMed Web of Science ®Google Scholar
• Albini A, Cesana BM, Motta D, Focà E, Gotti D, Calabresi A, . A randomized, pilot trial to evaluate glomerular filtration rate by creatinine or cystatin C in naïve HIV-infected patients after tenofovir/emtricitabine in combination with atazanavir/ritonavir or efavirenz. J Acquir Immune Defic Syndr 2012;59:18–24.
   PubMed Web of Science ®Google Scholar
• Rasch MG, Engsig FN, Feldt-Rasmussen B, Kirk O, Kronborg G, Pedersen C, . Renal function and incidence of chronic kidney disease in HIV patients: a Danish cohort study. Scand J Infect Dis2012 Jun 10. [Epub ahead of print]
   Google Scholar
• Young J, Schafer J, Fux CA, Furrer H, Bernasconi E, Vernazza P, . Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir. AIDS 2012;26:567–75.
   PubMed Web of Science ®Google Scholar
• van Griensven J, Sopheak T, Koole O, Verpooten GA, Lynen L. Determination of kidney function before tenofovir initiation: four-fold difference in need of tenofovir dose reduction depending on a method used. J Acquir Immune Defic Syndr 2011;57:e21–2.
   Google Scholar
• Vrouenraets SM, Fux CA, Wit FW, Garcia EF, Furrer H, Brinkman K, . Persistent decline in estimated but not measured glomerular filtration rate on tenofovir may reflect tubular rather than glomerular toxicity. AIDS 2011;25:2149–55.
   PubMed Web of Science ®Google Scholar
• Schmid S, Opravil M, Moddel M, Huber M, Pfammatter R, Keusch G, . Acute interstitial nephritis of HIV-positive patients under atazanavir and tenofovir therapy in a retrospective analysis of kidney biopsies. Virchows Arch 2007;450: 665–70.
   PubMed Web of Science ®Google Scholar
• Rockwood N, Mandalia S, Bower M, Gazzard B, Nelson M. Ritonavir-boosted atazanavir exposure is associated with an increased rate of renal stones compared with efavirenz, ritonavir-boosted lopinavir and ritonavir-boosted darunavir. AIDS 2011;25:1671–3.
   PubMedGoogle Scholar